Biobide

BBD BioPhenix is uniquely positioned developing zebrafish assays.  BBD BioPhenix is one of the most experiences zebrafish facilities and has developed and validated several fast and cost-effective toxicity and efficacy Assays. One of company´s main characteristic is working under GLP´s and automation environment providing prompt, clear and relevant information to develop chemical compound offering drug screening and disease model generation with zebrafish. 
The zebrafish embryo is an emerging model due to its properties (ease to manipulate, external fertilization and transparency) together with the need to apply the 3 Rs (Replacement, Reducement and Refinement of animals). This model has a high genetic homology with humans (over 85%) as well as important parallels in organogenesis and functional mechanisms. 
The zebrafish experimental model complies with the 3 R´s and offers an innovative and highly informative model in a cost-time efficient manner. 
BBD BioPhenix develops tailor made assays on zebrafish embryos and adults for customers and also provides standard or tailor made assay setting up.
BBD BioPhenix is fully committed to continuously offer new developments for preclinical testing on zebrafish alternative model to its customers. Therefore, the investment on R&D is relative high. The development of new assays is carried out as follows:
1.	Protocol development and setting up the study. This includes literature review, end points definition, experimental model selection (embryo, adult, zebrafish strain...), and methodology definition.
2.	Validation study. An internal study is carried out with reference compounds in order to determine the specificity and sensibility of the assay and verify study design and the end points applicability.
3.	Blinded screening. For further validation, the study using blinded investigational drugs is performed. This study is done in collaboration with the client.
4.	The assay is included in BBD BioPhenix pipeline and offered to clients including the option of adapting to clients´ request. 

The main assays set up by BBD BioPhenix are listed here below:
-	General toxicity: acute toxicity, teratogenicity.
-	Organ-specific toxicity: hepatotoxicity, cardiotoxicity, ototoxicity, neurotoxicity. 
-	Ecotoxicity and aquatic toxicity assays.
-	Efficacy assays: 
•	Antibiotic efficacy and antibiotic resistant assays: antimicrobial activity
•	Oncology: melanoma model, hepatocarcinoma model, anti-angiogenesis assay.
•	SNC: Parkinson´s disease, Alzheimer´s disease, depression, seizures and epilepsy, Huntington disease, mood disorders, schizophrenia, reward, circadian rhythm and other neurodegenerative diseases.
•	Others: metabolism and CV, immune…
-	Target validation and disease model generation: by Crips-cas, Talens  and Morpholinos.
In regards to the effectiveness of new antibacterial therapies, anti- Methicillin resistant Staphylococcus aureus (MRSA) assay is in development. In a second stage, other antimicrobial efficacy assays are on BBD BioPhenix R&D strategy, such as Pseudomonas aeruginosa, Acinetobacter baumanii, Klebsiella pneumonia, or Escherichia coli.